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Because of their fundamental role in generating electrical
impulses in many excitable tissues, sodium channels were among
the first voltage-gated ion channels to be extensively investigated.
Neurons bathed in a physiological solution containing 150mM
sodium ions respond to a threshold electrical stimulus by gener-
ating an action potential, whereas such a response is abolished
in a Na+-free medium. Since the classic 1952 studies of squid
axon sodium conductance, the Hodgkin and Huxley model of
sodium channel gating has served as a framework for under-
standing the time and voltage-dependent properties of these
channels (Hodgkin and Huxley, 1952). The advent of sophisti-
cated biochemical and molecular approaches eventually lead to
sodium channel purification (Hartshorne and Catterall, 1981)
and cloning (Noda et al., 1984). To date nine genes encod-
ing voltage-gated sodium channels are found in the human
genome. Dysfunction of these channels causes diseases known as
sodium channelopathies. In the 1990’s, the term “channelopathy”
was first coined to describe skeletal muscle hereditary diseases,
including periodic paralysis and myotonia, due to mutations in
the SCN4A gene encoding the muscle isoform of voltage-gated
sodium channels (Wang et al., 1993). Many of these aspects are
reviewed in this special issue dedicated to voltage-gated sodium
channels (Simkin and Bendahhou, 2011; Savio-Galimberti et al.,
2012).
Despite this impressive track record, there are still a number
of critical questions that need to be addressed regarding voltage-
gated sodium channels. Up to day, many studies have focused on
the main sodium channel α-subunit because it contains all the
requisites for a functioning channel, but it has become clear that
the α-subunit interacts with auxiliary β-subunits and other pro-
tein partners, that regulate the trafficking, the expression levels
and the function of these channels (Brackenbury and Isom, 2011;
Chahine and O’Leary, 2011; Savio-Galimberti et al., 2012).
Today voltage-gated sodium channels are the primary tar-
gets of drugs used as local anaesthetics, antiarrhythmics, anti-
convulsants, and neuroprotectants (Conte Camerino et al., 2007).
Several ongoing studies are aimed at understanding the intimate
drug-channel molecular interactions to design more efficacious
and safer drugs (Fozzard et al., 2011; Desaphy et al., 2012; Morris
et al., 2012). Gating properties of these channels are also affected
during trauma injury (Morris et al., 2012). As far as our knowl-
edge increases regarding sodium channel biophysics and involve-
ment in diseases, sodium channels represent a more, and more
attractive druggable targets for other conditions such as neuro-
pathic pain and general anesthesia (Theile and Cummins, 2011;
Herold and Hemmings, 2012). Voltage-gated sodium channels
are also the targets of numerous natural ligands, especially neu-
rotoxins, which provide important tools for the definition of the
channel structure–activity relationship, and ideally may serve as
lead compounds in the development of novel drugs (Stevens et al.,
2011). Thus, voltage-gated sodium channels will likely continue
to exert much interest for basic scientists and the pharmaceutical
industry. This topic is dedicated to voltage-gated sodium channels
their pharmacology and related diseases.
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